205 related articles for article (PubMed ID: 22916428)
41. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of hepatitis C infection. A revolution should not hide another].
Sogni P
Presse Med; 2014 Apr; 43(4 Pt 1):339-40. PubMed ID: 24661837
[No Abstract] [Full Text] [Related]
43. A new era of hepatitis C therapy begins.
Jensen DM
N Engl J Med; 2011 Mar; 364(13):1272-4. PubMed ID: 21449791
[No Abstract] [Full Text] [Related]
44. Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.
Lamers MH; Broekman MM; Boucher CA; Brouwer JT; Burger DM; van Hoek B; Hoepelman AI; de Knegt RJ; Reesink HW; Drenth JP; ; ;
Neth J Med; 2013 Sep; 71(7):377-85. PubMed ID: 24038567
[TBL] [Abstract][Full Text] [Related]
45. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
46. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
47. Hepatitis in 2010: the dawn of a new era in HCV therapy.
Ciesek S; Manns MP
Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):69-71. PubMed ID: 21293503
[TBL] [Abstract][Full Text] [Related]
48. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
49. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
[No Abstract] [Full Text] [Related]
50. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Manns MP; Vierling JM; Bacon BR; Bruno S; Shibolet O; Baruch Y; Marcellin P; Caro L; Howe AY; Fandozzi C; Gress J; Gilbert CL; Shaw PM; Cooreman MP; Robertson MN; Hwang P; Dutko FJ; Wahl J; Mobashery N
Gastroenterology; 2014 Aug; 147(2):366-76.e6. PubMed ID: 24727022
[TBL] [Abstract][Full Text] [Related]
51. De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).
Fabrizi F; Aghemo A; Moroni G; Passerini P; D'Ambrosio R; Martin P; Messa P
Dig Dis Sci; 2014 Mar; 59(3):691-5. PubMed ID: 24318802
[No Abstract] [Full Text] [Related]
52. L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
Cacoub P; Terrier B; Saadoun D
Presse Med; 2013 Apr; 42(4 Pt 2):523-7. PubMed ID: 23453499
[No Abstract] [Full Text] [Related]
53. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Hu CC; Chien RN
Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
[No Abstract] [Full Text] [Related]
54. Telaprevir for retreatment of HCV infection.
Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
[TBL] [Abstract][Full Text] [Related]
55. Response-guided therapy: optimizing treatment now and in the future.
Marcellin P; Rizzetto M
Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
[No Abstract] [Full Text] [Related]
56. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
[TBL] [Abstract][Full Text] [Related]
57. Telaprevir for the treatment of chronic hepatitis C infection.
Muir AJ
Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
[TBL] [Abstract][Full Text] [Related]
58. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
Burney T; Dusheiko G
Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
[TBL] [Abstract][Full Text] [Related]
59. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
[TBL] [Abstract][Full Text] [Related]
60. Severe renal impairment during triple therapy with telaprevir.
Carrier P; Chambaraud T; Vong C; Guillaudeau A; Debette-Gratien M; Jacques J; Legros R; Sautereau D; Essig M; Loustaud-Ratti V
Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):e69-71. PubMed ID: 24461554
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
